1370705-39-7

Basic information

• Product Name: 3-(Hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile
• Synonyms: 3-(Hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile
• CAS NO: 1370705-39-7
• Molecular Formula: C₇H₉NO
• Molecular Weight: 123.15246
• Mol File: 1370705-39-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(Hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile(1370705-39-7)
• EPA Substance Registry System: 3-(Hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile(1370705-39-7)

Safety Data

• Hazardous Substances Data: 1370705-39-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-(Hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile is used as a building block in organic synthesis for the creation of more complex molecules. Its unique bicyclic structure and functional groups make it a versatile component in the synthesis of various organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-(Hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile is used as a starting material for the development of new drugs. Its potential as a precursor for the synthesis of bioactive molecules makes it a promising candidate for drug discovery and medicinal chemistry.
Used in Chemical Research and Exploration:
3-(Hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile is utilized as a subject of study in chemical research to explore its unique structure, properties, and potential applications. Further investigation is needed to understand its full potential and to identify new areas where it can be applied effectively.

Upstream product

• 56842-95-6 bicyclo<1.1.1>pentane-1,3-dicarboxylic acid 
• 115913-30-9 1,1′-(bicyclo[1.1.1]pentane-1,3-diyl)bis(ethan-1-one) 
• 83249-10-9 3‐(methoxycarbonyl)bicyclo[1.1.1]pentane‐1‐carboxylic acid 
• 110371-22-7 methyl 3-(chlorocarbonyl)bicyclo<1.1.1>pentane-1-carboxylate 
• 115913-31-0 1,3-bis(chlorocarbonyl)bicyclo<1.1.1>pentane 
• 115913-32-1 dimethyl bicyclo<1.1.1>pentane-1,3-dicarboxylate 
• 156329-62-3 3-(hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile 
• 156329-77-0 methyl 3-carbamoylbicyclo<1.1.1>pentane-1-carboxylate 

Downstream Products

• 1370705-40-0 (R)-2-{4-chloro-N-[(3-cyanobicyclo[1.1.1]pentan-1-yl)methyl]phenylsulfonamide}-5,5,5-trifluoropentanamide 
• 1370705-38-6 (R)-2-{N-{[3-(1,2,4-oxadiazol-3-yl)bicyclo[1.1.1]pentan-1-yl]-methyl}-4-chlorophenylsulfonamido}-5,5,5-trifluoropentanamide 

Relevant articles and documents

Quinuclidine derivative, method for preparing same and application of quinuclidine derivative

The invention relates to a quinuclidine derivative, a pharmaceutically acceptable salt, pro-drug and solvent compound of the quinuclidine derivative, a method for preparing the quinuclidine derivative, a drug composition with the quinuclidine derivative and the pharmaceutically acceptable salt, pro-drug and solvent compound and pharmaceutical application of the quinuclidine derivative. The quinuclidine derivative, the pharmaceutically acceptable salt, pro-drug and solvent compound, the method, the drug composition and the pharmaceutical application have the advantage that the compound is excellent in M3 receptor antagonist activity and accordingly can be used as a novel efficient drug for chronic obstructive pulmonary diseases.

Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor

Replacement of the central, para-substituted fluorophenyl ring in the γ-secretase inhibitor 1 (BMS-708,163) withthe bicyclo[1.1.1]pentane motif led to the discovery of compound 3, an equipotent enzyme inhibitor with significant improvements in passive permeability and aqueous solubility. The modified biopharmaceutical properties of 3 translated into excellent oral absorption characteristics (～4-fold Cmax and AUC values relative to 1) in a mouse model of γ-secretase inhibition. In addition, SAR studies into other fluorophenyl replacements indicate the intrinsic advantages of the bicyclo[1.1.1]pentane moiety over conventional phenyl ring replacements with respect to achieving an optimal balance of properties (e.g., γ-secretase inhibition, aqueous solubility/permeability, in vitro metabolic stability). Overall, this work enhances the scope of the [1.1.1]-bicycle beyond that of a mere spacer unit and presents a compelling case for its broader application as a phenyl group replacement in scenarios where the aromatic ring count impacts physicochemical parameters and overall drug-likeness.